Who are QLG1091's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SINECATECHINS, PODOFILOX, POLIDEXIDE SULFATE, SUTILAINS, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Latanoprost plus adjunctive glaucoma medication.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/qlg1091.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

QLG1091 — Competitive Intelligence Brief

QLG1091 (QLG1091) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: small molecule. Area: unknown.

phase 3 small molecule unknown unknown Small molecule Live · refreshed every 30 min

Target snapshot

QLG1091 (QLG1091) — Qilu Pharmaceutical Co., Ltd.. QLG1091 is a small molecule drug that targets the molecular target.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
QLG1091 TARGET	QLG1091	Qilu Pharmaceutical Co., Ltd.	phase 3	small molecule	unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
Open-label, PK Cohort (Cohort B): ponsegromab low dose	open-label-pk-cohort-cohort-b-ponsegromab-low-dose	Pfizer	marketed	Unknown	Unknown
Latanoprost plus adjunctive glaucoma medication	Latanoprost plus adjunctive glaucoma medication	Sight Sciences, Inc.	marketed	Prostaglandin analog with adjunctive glaucoma agent	FP prostaglandin receptor (latanoprost component); adjunctive target unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (small molecule class)

Pfizer · 5 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 4 drugs in this class
Jiangsu HengRui Medicine Co., Ltd. · 3 drugs in this class
Avalo Therapeutics, Inc. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Cipla BioTec Pvt. Ltd. · 1 drug in this class
ChemRar Research and Development Institute, LLC · 1 drug in this class
Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
Dilafor AB · 1 drug in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). QLG1091 — Competitive Intelligence Brief. https://druglandscape.com/ci/qlg1091. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab